// App-Quantinova.ai

: A phase II trial of zoptarelin doxorubicin in castration- and taxane-resistant prostate cancer.

Researchers

Presenter

  • Steven Yu

Principal Investigators

  • Kanthi Athreya

  • Stephen V. Liu

  • Andrew V. Schally

  • Susan G. Groshen

  • Denice D Tsao-Wei

  • David I. Quinn

  • Tanya B. Dorff

  • Shigang Xiong

  • Jacek Pinski

  • Jurgen Engel

Medical Centers

  • University of Southern California, Los Angeles, CA

  • University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA

  • Georgetown University, Washington, DC

  • Miami VA Medical Center

  • University of Miami Miller School of Medicine, Miami, FL

  • University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA

  • Keck School of Medicine of University of Southern California, Los Angeles, CA

  • USC Norris Comprehensive Cancer Center, Los Angeles, CA

  • Aeterna Zentaris, Quebec, QC, Canada

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • Zoptarelin doxorubicin

  • Androgen Tear

  • taxane

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT01240629

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved